Houston maintains its top 3 position on ranking of cities that best attract biz

by the numbers

For the third year in a row, Houston ranked high on the list of major metros attracting new business. Photo via Getty Images

According to a recent report, Houston is still one of the top city in the United States for attracting new companies.

The ranking, which was researched and published by Site Selection Magazine, found that the Houston-The Woodlands-Sugar Land region attracted 255 business projects last year. This put the metro in the third place of the list that analyzed larger regions.

It's the third year in third place for Houston, and the city had a year over year improvement in number of deals; 2021 reported 213 new business projects in Houston. In fact, the top three cities – Chicago, Dallas, and Houston, respectively — has remained the same for all three years. For 2022, the Chicago metro garnered 448 projects, while Dallas-Fort Worth-Arlington reportedly had 426 projects.

The report also called out a recent statistic from Kastle Systems, which was based on building access control data. The stat found that among 10 major cities analyzed based on t week of February, Houston was one of three metros that had a returned-worker percentages higher than 50 percent.

According to the Greater Houston Partnership data, new business accounted for more than 50 percent of business announcements in 2022. GHP's data varied from Site Selection's due to a difference in reporting methods, but the organization's research identified 199 new business announcements in the Houston area in 2022.

The NBAs included new businesses, HQ announcements, and expansions. The GHP data included information about these deals' industry verticals — and the manufacturing sector accounted for almost a third of the total NBAs in 2022.

Chart via houston.org

The GHP also rounded up a few of the most prominate deals reported in their data. According to the Partnership, here were more details about these NBAs:

  • Orsted — an offshore wind developer from Denmark is expanding its presence in Texas by establishing a new office in the Woodlands. The move is expected to create up to 100 jobs in the region.
  • Syzygy Plasmonics — a Houston-based energy 2.0 company is expanding its operations to Pearland. The new location will serve as HQ, R&D, and manufacturing for its deep-decarbonization platform, creating up to 120 jobs.
  • Alfred Talke Logistic Services — a German logistics firm is establishing a new facility in the region, serving as its U.S. headquarters. This project represents a $25 million investment and will create 240 jobs.

Trevor Best, co-founder and CEO of Syzygy, first discussed the company's expansion last year on the Houston Innovators Podcast.

"What we're seeing is the market's appetite for our kind of technology — deep tech for decarbonization in energy and chemicals — is really high. If we want to meet global demand for our product, we need to get ready to scale," he says on the show.


From Your Site Articles
Houston usurped the Dallas metro to grab the No. 2 ranking in the United States for big cities attracting corporate relocation and expansion projects. Getty Images

Report: Houston ranked No. 2 in the country for corporate relocation, expansion projects landed in 2019

big business

In Texas, Houston rules the corporate relocation and expansion kingdom.

Site Selection magazine ranks Houston second among large U.S. metro areas for the number of corporate relocation and expansion projects landed in 2019. That's up two spots from the previous year's ranking.

On the new list, published in the magazine's March issue, Houston replaces Dallas-Fort Worth in the No. 2 spot among metros with at least 1 million residents, pushing DFW down to No. 3. Austin takes the No. 6 spot.

Last year, Houston landed 276 projects that met the magazine's ranking criteria. With 416 projects, Chicago earned the No. 1 spot. Dallas-Fort Worth scored 261 projects in 2019, while Austin snagged 95.

Qualifying projects for Site Selection's rankings must have a minimum investment of $1 million, create at least 20 new jobs, or involve at least 20,000 square feet of new space.

A couple of notable Houston corporate relocations or expansions in 2019 were:

"This latest ranking is more evidence of Houston's strength as a destination for corporate relocation and investment," Bob Harvey, president and CEO of the Greater Houston Partnership, says in a March 3 statement. "Our low cost of doing business, access to quality talent, and pro-growth mentality continue to make Houston an attractive place for companies across the country and around the world looking for expansion and relocation opportunities. Our strong, diverse economy is a big part of what makes Houston a great global city."

Commercial real estate services company Colliers International notes that Houston is one of the country's most competitive cities for corporate relocation and expansion.

"Houston's ability to foster continued expansion in future-growth industries responsible for generating high-quality, well-paid jobs across all business sectors has placed it in the top tier among U.S. cities," Colliers International says. "With its numerous business advantages, Houston is well positioned to successfully compete in today's global marketplace."

Among those advantages, Colliers says, are:

  • Two major airports
  • Massive seaport
  • Extensive rail and road infrastructure
  • 90 foreign consulates

In February 2019, René Lacerte, founder and CEO of Bill.com, said the Palo Alto, California-based company picked Houston for its first U.S. outpost following an "extensive national search." Bill.com settled on Houston because of its talent pool, quality of life, and business-friendly environment, he said.

Houston Mayor Sylvester Turner has said the Bill.com expansion represents a "another great example of Houston's building momentum as a leading digital tech hub."

A second example is Amazon Web Services' July 2019 expansion in Houston. Kris Satterthwaite, the company's Gulf Coast enterprise sales leader, praised the city as "a fantastic place to live and work," and as having "a strong local economy that we look forward to investing in and growing together [with]."

The Houston-DFW-Austin trifecta of top-performing markets for corporate relocation and expansion in 2019 helped propel Texas to win Site Selection's Governor's Cup Award for the eighth consecutive year.

In accepting the award, Gov. Greg Abbott called Texas "the most dynamic economy in the nation."

"Texas' skilled, diverse, and ever-expanding workforce drives our booming economy," Abbott said. "I want to thank all of our local, regional and statewide economic development teams for their work to expand economic opportunity in Texas, as well as the companies that continue to invest and create more jobs throughout the Lone Star State."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings